Table 1.
Characteristics of patients with travel-related (TRB) and domestically acquired (DAB) bacteremia
| Characteristics | TRB (n = 76) | DAB (n = 235) | ||
|---|---|---|---|---|
| Age | ||||
| Median (years, range) | 36 | (0-79) | 64 | (0-96) |
| <65 years (numbers, percent) | 64 | (84.2) | 123 | (52.3) |
| ≥65 years | 12 | (15.8) | 112 | (47.7) |
| Sex | ||||
| Males | 49 | (64.5) | 118 | (50.2) |
| Admitted to an infectious diseases unita | 29/64 | (45.3) | 8/163 | (4.9) |
| Comorbidity indexb | ||||
| 0 | 54 | (71.1) | 69 | (29.4) |
| 1-2 | 11 | (14.5) | 91 | (38.7) |
| ≥3 | 11 | (14.5) | 75 | (31.9) |
| Individuals with malignancy | ||||
| Hematological malignanciesc | 3 | (3.9) | 23 | (9.8) |
| Other malignancies | 6 | (7.9) | 36 | (15.3) |
| Other comorbidities | ||||
| Dialysisd | 0 | (0.0) | 3 | (1.3) |
| Organ transplantation | 0 | (0.0) | 2 | (0.9) |
| Alcoholisme | 3 | (3.9) | 21 | (8.9) |
| Previous gastric surgeryf | 3 | (3.9) | 5 | (2.1) |
| Drug therapy | ||||
| Chemotherapy & immunomodulatory agents | 5 | (6.6) | 33 | (14.0) |
| Corticosteroid therapy | 2 | (2.6) | 30 | (12.8) |
| PPI & H2-antagonist | 7 | (9.2) | 66 | (28.1) |
| Antacids | 0 | (0.0) | 8 | (3.4) |
| Length of hospital stay (median, IQR) | 8 days | (5-11) | 11 days | (6-17) |
| An extraintestinal site of infection | 5 | (6.6) | 31 | (13.2) |
| Mortality by age group | ||||
| <65 years | ||||
| 30-day | 3 | (4.7) | 11 | (8.9) |
| 90-day | 4 | (6.3) | 12 | (9.8) |
| ≥65 years | ||||
| 30-day | 0 | (0.0) | 30 | (26.8) |
| 90-day | 1 | (8.3) | 40 | (35.7) |
| Overall | ||||
| 30-day | 3 | (3.9) | 41 | (17.4) |
| 90-day | 5 | (6.6) | 52 | (22.1) |
a Only numbers from North Jutland and Aarhus Counties.
b Charlson comorbidity index.
c Lymphoma, leukaemia and myeloma; Patients with myeloproliferative disease or myelodysplastic syndrome also included.
d Dialysis due to complications to the bacteremia not included.
e Both history of present and previous alcoholism included.
f Gastrectomy, vagotomy, gastric bypass.